La fin des haricots? La santé des plantes de haricot en production de semence artisanale et biologique
Diverse speeche and writing (2014)
Ce poster a servi de support pour animer des ateliers pratiques sur les potagères (3*5min) dans le cadre de cette journée professionnelle sur les semences paysannes. Parmis les participants, il y avait ... [more ▼]
Ce poster a servi de support pour animer des ateliers pratiques sur les potagères (3*5min) dans le cadre de cette journée professionnelle sur les semences paysannes. Parmis les participants, il y avait surtout des producteurs et des représentants d'ONGs. [less ▲]Detailed reference viewed: 27 (2 ULg)
La fin des haricots?
Conference given outside the academic context (2013)
Afin de répondre aux besoins particuliers des agricultures biologiques et paysannes, paysans et chercheurs s’engagent en partenariat pour faire vivre une diversité de plantes cultivées et réaliser des ... [more ▼]
Afin de répondre aux besoins particuliers des agricultures biologiques et paysannes, paysans et chercheurs s’engagent en partenariat pour faire vivre une diversité de plantes cultivées et réaliser des recherches adaptées. Dans le cadre de cette conférence, nous présentons des projets de sélection participative menés en Bretagne, une des régions pionnières en Europe. Nous discuterons une première démarche de recherche participative faite au Luxembourg et les enjeux de ces recherches. [less ▲]Detailed reference viewed: 73 (9 ULg)
La fin du certificat de bonnes conduite, vie et mœurs : chronique d’une mort annoncée
in Revue de Droit Pénal et de Criminologie (2007)Detailed reference viewed: 43 (2 ULg)
La fin du Mésolithique et le Néolithique au Proche-Orient
in Le génie de l'Homme. Des origines à l'écriture (1995)Detailed reference viewed: 24 (1 ULg)
La fin du Paléolithique moyen dans le Nord de l’Europe : la question des origines du Lincombien-Ranisien-Jerzmanowicien
in Depaepe, Pascal; Goval, Emilie; Koehler, Héloïse (Eds.) et al Les plaines du Nord-Ouest : carrefour de l’Europe au Paléolithique moyen ? (2015)Detailed reference viewed: 57 (2 ULg)
La fin du théologico-politique chez Hobbes et chez Spinoza
Conference given outside the academic context (2005)Detailed reference viewed: 6 (0 ULg)
Fin flickering and associated sounds in the cichlid fish Ophthalmotilapia ventralis: a preliminary study.
Kever, Loïc ; Poncin, Pascal ; Parmentier, Eric
Fin flickering was defined as rapid movements of the fins. The behavioral function of such movements is however not well established. Depending on the species investigated, they were considered as comfort ... [more ▼]
Fin flickering was defined as rapid movements of the fins. The behavioral function of such movements is however not well established. Depending on the species investigated, they were considered as comfort movements (e.g. removal of minor irritations) or alarm for young. In the cichlid Etroplus maculatus they allow homogenous repartition of eggs on the substrate. We studied visual and acoustical behavior of five Ophthalmotilapia ventralis (two males and three females) reared in a 240 l tank. Pectoral fin flickering associated with sound production was often observed, especially from fish that established a territory. With the exception of the butterflish Chaetodon mutlicinctus and gouramis, this aspect of fin flickering is generally overlooked in teleosts. First observations support the fact that sounds (peak frequency and pulse duration: 562±95 Hz and 14±5 ms, respectively) are not emitted during all kinds of fin movements but mainly during some caudo-rostral horizontal fin sweeps. In-depth studies are however required to better characterize the movements and understand what morphological traits are responsible for the sound production. Further investigations are also needed to determine if fin flickering has a role in O. ventralis social interactions [less ▲]Detailed reference viewed: 48 (6 ULg)
La fin justifie les moyens. Éthique et violence dans les Cahiers pour une morale
Conference (2004, June 24)Detailed reference viewed: 7 (0 ULg)
Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg
; JERUSALEM, Guy ; et al
in Cancer Research. Supplement (2012, December 15), 72(24), 1-4Detailed reference viewed: 29 (10 ULg)
Final conclusions of the International Colloquium "From industrial to social networks. Cultural history, political economy and society of the digital age"
Geuens, Geoffrey ;
Conference (2011, October 21)Detailed reference viewed: 47 (17 ULg)
Final farewell to Jos R.T.C. Roelandt, former European Society of Cardiology Gold Medallist and founding editor of the European Journal of Echocardiography.
Lancellotti, Patrizio ;
in European heart journal (2015), 36(1), 8-9Detailed reference viewed: 29 (0 ULg)
Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial.
; Jerusalem, Guy ; et al
in Journal of the National Cancer Institute (2014), 106(1), 337
BACKGROUND: At the time of the initial analysis of overall survival (OS) for the Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) randomized, double-blind, phase III trial ... [more ▼]
BACKGROUND: At the time of the initial analysis of overall survival (OS) for the Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) randomized, double-blind, phase III trial, approximately 50% of patients had died. A final analysis of OS was subsequently planned for when 75% of patients had died. METHODS: Patients were randomly assigned 1:1 to fulvestrant 500 mg administered as two 5-mL intramuscular injections on days 0, 14, and 28 and every 28 (+/-3) days thereafter or fulvestrant 250 mg administered as two 5-mL intramuscular injections (one fulvestrant and one placebo [identical in appearance to study drug]) on days 0, 14 (two placebo injections only), and 28 and every 28 (+/-3) days thereafter. OS was analyzed using an unadjusted log-rank test. No adjustments were made for multiplicity. Serious adverse events (SAEs) and best response to subsequent therapy were also reported. All statistical tests were two-sided. RESULTS: In total, 736 women (median age = 61.0 years) were randomly assigned to fulvestrant 500mg (n = 362) or 250mg (n = 374). At the final survival analysis, 554 of 736 (75.3%) patients had died. Median OS was 26.4 months for fulvestrant 500mg and 22.3 months for 250mg (hazard ratio = 0.81; 95% confidence interval = 0.69-0.96; nominal P = .02). There were no clinically important differences in SAE profiles between the treatment groups; no clustering of SAEs could be detected in either treatment group. Type of first subsequent therapy and objective responses to first subsequent therapy were well balanced between the two treatment groups. CONCLUSIONS: In patients with locally advanced or metastatic estrogen receptor-positive breast cancer, fulvestrant 500mg is associated with a 19% reduction in risk of death and a 4.1-month difference in median OS compared with fulvestrant 250mg. Fulvestrant 500mg was well tolerated, and no new safety concerns were identified. [less ▲]Detailed reference viewed: 50 (4 ULg)
Final Report of the Contract of technical assistance 03-UCH0401 of LabSET to the Piloting Unit of the Reform del Pregrado (Chile)
Leclercq, Dieudonné ; Poumay, Marianne ; Dupont, Chantal
Report (2008)Detailed reference viewed: 25 (3 ULg)
Final Report of the Solar Influences Data Centre Space Weather Pilot Project
; ; Warnant, René et al
Report (2005)Detailed reference viewed: 10 (0 ULg)
Final Report on the Belgian Survey on Experience of racial Discrimination
The report refers to the Belgian part of an european survey on experience of racial discrimination. The survey was carried out among four communities (Turkish, Morrocan, Chinese and Congolese) in three ... [more ▼]
The report refers to the Belgian part of an european survey on experience of racial discrimination. The survey was carried out among four communities (Turkish, Morrocan, Chinese and Congolese) in three different cities of Belgium (Gent, Brussels, Liege). The result of the survey are analysed in a comparative way between communities and cities. [less ▲]Detailed reference viewed: 23 (7 ULg)
FINAL REPORT PHASE I "Impact of Phenology and Environmental Conditions on BVOC Emissions from Forest Ecosystems” «IMPECVOC»
; ; et al
Report (2008)Detailed reference viewed: 32 (5 ULg)
FINAL REPORT PHASE II "Impact of Phenology and Environmental Conditions on BVOC Emissions from Forest Ecosystems" "IMPECVOC"
; ; et al
Report (2011)Detailed reference viewed: 10 (1 ULg)
Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial.
; ; et al
in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology (2011), 6(7), 805-12
AIMS: The SEISMIC study was an open-label, prospective, randomised study to assess the safety and feasibility of percutaneous myoblast implantation in heart failure patients with implanted cardioverter ... [more ▼]
AIMS: The SEISMIC study was an open-label, prospective, randomised study to assess the safety and feasibility of percutaneous myoblast implantation in heart failure patients with implanted cardioverter-defibrillators (ICD). METHODS AND RESULTS: Patients were randomised 2:1 to autologous skeletal myoblast therapy vs. optimal medical treatment. The primary safety end-point was defined as the incidence of procedural and device related serious adverse events, whereas the efficacy endpoints were defined as the change in global LVEF by MUGA scan, change in NYHA classification of heart failure and in the distance achieved during a six-minute walk test (6MW) at 6-month follow-up. Forty subjects were randomised to the treatment arm (n=26), or to the control arm (n=14). There were 12 sustained arrhythmic events and one death after episodes of ventricular tachycardia (VT) in the treatment group and 14 events in the control group (P=ns). At 6-month follow-up, 6MW distance improved by 60.3+/-54.1?meters in the treated group as compared to no improvement in the control group (0.4+/-185.7?meters; P=ns). In the control group, 28.6% experienced worsening of heart failure status (4/14), while 14.3% experienced an improvement in NYHA classification (2/14). In the myoblast-treatment arm, one patient experienced a deterioration in NYHA classification (8.0%), whereas five patients improved one or two classes (20.0%; P=0.06). However, therapy did not improve global LVEF measured by MUGA at 6-month follow-up. CONCLUSIONS: These data indicate that implantation of myoblasts in patients with HF is feasible, appears to be safe and may provide symptomatic relief, though no significant effect was detected on global LVEF. [less ▲]Detailed reference viewed: 94 (0 ULg)